News stories about MannKind Corporation (NASDAQ:MNKD) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. MannKind Corporation earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.9002564535112 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- MannKind (MNKD) Announces 10.17M Share Registered Direct Common Offering at $6/Sh (streetinsider.com)
- MannKind (MNKD) Stock: Get In On The Discount (cnafinance.com)
- MannKind’s stock tumbles after share offering, in wake of recent tripling in price (finance.yahoo.com)
- Why Rite Aid, MannKind, and Sears Holdings Slumped Today (finance.yahoo.com)
- 7 Essential Rules for Investing in Biotech Stocks (finance.yahoo.com)
Shares of MannKind Corporation (MNKD) opened at 5.47 on Friday. The company has a market cap of $572.61 million, a price-to-earnings ratio of 4.12 and a beta of 3.16. The stock’s 50 day moving average is $2.66 and its 200-day moving average is $1.64. MannKind Corporation has a 52 week low of $0.67 and a 52 week high of $6.96.
A number of research firms have issued reports on MNKD. Zacks Investment Research upgraded shares of MannKind Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday. Maxim Group restated a “buy” rating on shares of MannKind Corporation in a research report on Friday, September 1st. ValuEngine cut shares of MannKind Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, HC Wainwright began coverage on shares of MannKind Corporation in a research report on Tuesday. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. MannKind Corporation has an average rating of “Hold” and a consensus price target of $0.92.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MannKind Corporation (MNKD) Stock Price” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mannkind-corporation-mnkd-stock-price.html.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
What are top analysts saying about MannKind Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MannKind Corporation and related companies.